



TMA DoD Pharmacoeconomic Center Fort Sam Houston, TX

MTF Quarterly Webcast December 8, 2011

Introduction

- ▶ Greetings from the PEC
- ▶ Purpose of the Quarterly MTF Webcast
- ▶ DCO Ground Rules
 - Type questions into the DCO system
 - Put on mute, not on hold
 - Contingency plan if DCO system stops working


Outline

- ▶ Introduction
- ▶ MTF Corner: Business Intelligence tools (Best Pharm and National Contracts—Major Hamilothoris)
- ▶ Review of August 2011 P&T Committee Meeting (Dr Meade)
- ▶ Overview of November 2011 P&T Committee Meeting (Dr Meade)

MTF Corner

Defense Logistics Agency –
Troop Support Medical Customer
Pharmacy Operations Center (CPOC)

Maj Achilles Hamilothis



CPOC Objectives

- ▶ Enhance customer outreach to the pharmaceutical community
 - Train/assist customers in use of source optimization tools and processes; i.e., Best Pharm & National Contract Compliance Reports, Universal Data Repository (UDR), Electronic Catalog (ECAT), etc.
 - Assist in finding sources/alternatives for non-Prime Vendor items
 - Help mfr's manage off-patent Rx to generic conversions
 - Help Services track and trend their savings
 - Educate customers on Medical Air Bridge & Reverse Distributor
 - Serve as DoD's pharmaceutical customer advocate at DLA
 - Provide customer feedback to Troop Support Medical business managers to make recommended changes and improve IT tools
- ▶ Coordinate Medical Supply Chain Actions/Alerts with other key players such as the Pharmacoeconomic Center (PEC), Pharm/Log Consultants, Prime Vendors, Manufacturers, Information Technology enablers, etc.

DMMonline Site Login Page



DEFENSE LOGISTICS AGENCY DLA Troop Support Medical Supply Chain - DMMonline

[Prime Vendor Program](#)

[Pharmaceuticals](#)

[Medical/Surgical](#)

[Equipment](#)

[Readiness](#)

[ECAT](#)

[Site Login](#)

[Achilles Hamilothoris](#)

[Logout](#)

DLA's Medical Supply Chain Portal

DMLSS-Wholesale

Our mission is to modernize the entire military health care logistics supply chain.

Our Logistics Applications ▾

Customer Services

- [Contact Medical](#)
- [Order a product](#)
- [Submit a Materiel Complaint](#)
- [Report Discrepancy to DLA](#)
- [Update my profile](#)

Supplier Information

- [Sell my products](#)
- [Learn about DAPAs](#)
- [More Supplier Information](#)

Medical Supply Chain (MSC) Mission

This is the official website for the DLA Troop Support Medical Supply Chain (MSC). Our mission is to provide the military medical community the products and services needed every day for every crisis around the world. Our goal is to provide our customers and commercial trading partners a convenient, state-of-the-art, readily accessible web portal that enables them to efficiently and effectively accomplish their business.

EARLE SMITH II, COL, MSC, USA

Director

Medical Supply Chain

Medical/Surgical PV Gen IV Contract Post Award Conference

The official power point slide show presented at the conference explaining all the Gen IV contract details. [Conference Slideshow](#)

<https://www.medical.dla.mil/>

DMMonline Pharmaceutical

Pharm - Depot/DVD

- Pharm Prime Vendor

Division Info

- Vaccine Updates
- Depot Stockage
- Depot Stock Item List
- Cold Chain Packaging

Related Information

- Pharm Search Methods
- DEA Receipt Verification

Helpful Links

- Customer Assistance
- Site Map
- Visiting Our Organization
- DLA Troop Support Website
- Government Medical Websites



[Return to DMMonline Home](#)

Pharmaceutical Division Overview

The Pharmaceutical Division procures and manages the full spectrum of pharmaceutical agents. Below are the other management responsibilities of the Medical Supply Chain's Pharm Division.

Free Pharmaceutical and diagnostics products are [available for issue](#).

Pharmaceutical Prime Vendor (PPV)

A PPV is a single distributor of brand specific Pharmaceutical supplies, who provides next day delivery. Our PPV's are leading distributors in the pharmaceutical distribution industry. Contracts covering the entire United States, Europe, and the Pacific are currently in place. [Prime Vendor Overview](#)

National Contracts

The Medical Supply Chain provides comprehensive listing of the drugs and drug classes that have been contracted. [Learn More](#)

Vaccines

The Pharmaceutical Division offers most vaccines for purchase by eligible customers. We are in partnership with the Department of Health and Human Services to support the U.S. vaccine stockpile program. [View Vaccine Availability](#)

Depot

Depot stockage had been the primary method of supporting military customers. With the advent of alternate distribution techniques, as well as a renewed focus on the cost of holding inventory, most items have been removed from depot management in favor of Pharmaceutical Prime Vendor support. Currently, there are 46 pharmaceutical items stored in Defense Logistics Agency (DLA) depots. [Learn More](#)

Cold Chain Packaging

A list of geographic areas should be Cold Chain Packaged according to the indicated Packaging Protocols and related documentation. [Cold Chain Section](#)

Reverse Distribution

DLA Troop Support offers national contracts for the purpose of returning pharmaceuticals and medical supplies dispensed by the Pharmacy and any related waste materials that may arise due to un-returnable pharmaceuticals. [Learn More](#)

Best Pharm Report

- ▶ Best Pharm Report is a helpful guide to let you know what other contracts may be available via the prime vendor in order to save taxpayer \$\$
- ▶ Report cannot take issues into consideration, such as manufacturer backorders, shortages, etc.
- ▶ Report takes packaging into consideration—default is same size but could select all sizes
- ▶ You must determine if the suggested substitute is appropriate for your facility
 - Unit dose; bottles of 30 vs. 100 vs. 5000
- ▶ If you want to switch, please notify your prime vendor providing the NDC and estimated usage

BP Results Example—Default Same Size

Display Total Purchases Report

Show Package Size Alternatives

Display Printable Potential Savings report in Excel

NDC	Drug Name	DEA Sched	Current Avg Unit Price	Current Pkg	UoM	Best NDC	Best NDC Pkg	Best UoM Price	Potential Savings Per UoM	Orange Book CD	Total Purchased Qty	Total Purchases	Potential Savings
00078017915	LAMISIL 250 MG TABLET	0	\$314.52	30	\$10.48	42291080530	30	\$0.15	\$10.34	AB	60	\$18,871.20	\$18,603.54
00173064255	LAMICTAL 100 MG TABLET	0	\$331.18	100	\$3.31	59746024601	100	\$0.04	\$3.28	AB	49	\$16,227.82	\$16,053.87
64764004613	PREVACID DR 30 MG CAPSULE	0	\$369.56	100	\$3.70	00781235501	100	\$0.98	\$2.72	AB	33	\$12,195.48	\$8,960.49
00173063302	LAMICTAL 25 MG TABLET	0	\$298.29	100	\$2.98	59746024501	100	\$0.03	\$2.95	AB	25	\$7,457.25	\$7,379.75
00173056504	VALTREX 1 GM CAPLET	0	\$260.57	30	\$8.69	63304090530	30	\$1.66	\$7.02	AB	34	\$8,859.38	\$7,165.16
00173064360	LAMICTAL 150 MG TABLET	0	\$204.93	60	\$3.42	59746024760	60	\$0.05	\$3.36	AB	33	\$6,762.69	\$6,660.32
00173064460	LAMICTAL 200 MG TABLET	0	\$216.83	60	\$3.61	59746024860	60	\$0.06	\$3.55	AB	24	\$5,203.92	\$5,118.67
00074712613	DEPAKOTE ER 500 MG TABLET	0	\$153.76	100	\$1.54	00378047301	100	\$0.15	\$1.38	AB	31	\$4,766.56	\$4,290.40
00074455219	SYNTHROID 50 MCG TABLET	0	\$90.00	1000	\$0.09	00781518110	1000	\$0.00	\$0.09	AB	47	\$4,230.00	\$4,225.30
00149071001	MACROBID 100 MG CAPSULE	0	\$363.71	100	\$3.64	00185012201	100	\$0.13	\$3.51	AB	12	\$4,364.52	\$4,210.92
00378207510	LISINOPRIL 20 MG TABLET	0	\$110.82	1000	\$0.11	00143126810	1000	\$0.03	\$0.08	AB	52	\$5,762.70	\$4,046.68

BP Results Example—Size Alternatives


Display Total Purchases Report

Show Package Size Alternatives

Display Printable Potential Savings report in Excel

NDC	Drug Name	DEA Sched	Current Avg Unit Price	Current Pkg	UoM	Best NDC	Best NDC Pkg	Best UoM Price	Potential Savings Per UoM	Orange Book CD	Total Purchased Qty	Total Purchases	Potential Savings
00173093310	VALTREX 500 MG CAPLET	0	\$448.43	90	\$4.98	63304090430	30	\$0.85	\$4.13	AB	138	\$61,883.34	\$51,272.94
00173056510	VALTREX 1 GM CAPLET	0	\$784.78	90	\$8.72	63304090530	30	\$1.66	\$7.06	AB	42	\$32,960.76	\$26,682.18
00078017915	LAMISIL 250 MG TABLET	0	\$314.52	30	\$10.48	42291080530	30	\$0.15	\$10.34	AB	60	\$18,871.20	\$18,603.54
00185041505	BUPROPION SR 150 MG TABLET	0	\$823.27	500	\$1.65	00591354125	250	\$0.10	\$1.54	AB	23	\$18,935.21	\$17,748.41
00310020130	ARIMIDEX 1 MG TABLET	0	\$195.71	30	\$6.52	00378603477	90	\$0.20	\$6.32	AB	93	\$18,201.03	\$17,638.57
00173064255	LAMICTAL 100 MG TABLET	0	\$331.18	100	\$3.31	59746024610	1000	\$0.04	\$3.28	AB	49	\$16,227.82	\$16,053.87
00173064255	LAMICTAL 100 MG TABLET	0	\$331.18	100	\$3.31	59746024601	100	\$0.04	\$3.28	AB	49	\$16,227.82	\$16,053.87
00078045705	TRILEPTAL 600 MG TABLET	0	\$372.69	100	\$3.73	00054009925	600	\$0.05	\$3.68	AB	27	\$10,062.63	\$9,928.17
64764004613	PREVACID DR 30 MG CAPSULE	0	\$369.56	100	\$3.70	00781235501	100	\$0.98	\$2.72	AB	33	\$12,195.48	\$8,960.49
00173063302	LAMICTAL 25 MG TABLET	0	\$298.29	100	\$2.98	59746024505	500	\$0.03	\$2.95	AB	25	\$7,457.25	\$7,379.75
00173063302	LAMICTAL 25 MG TABLET	0	\$298.29	100	\$2.98	59746024501	100	\$0.03	\$2.95	AB	25	\$7,457.25	\$7,379.75
00173056504	VALTREX 1 GM CAPLET	0	\$260.57	30	\$8.69	63304090530	30	\$1.66	\$7.02	AB	34	\$8,859.38	\$7,165.16

Best Pharmacy Report Tracking - DoD Pharm Potential Excess Cost



* Please note there are instances when contract items may be unavailable due to variables such as shortages, facilities may need to set up monthly prime vendor (PV) requirements , time needed for PV to stock, Clinical Decisions, etc.

DMMonline Menu—NCCR



DEFENSE LOGISTICS AGENCY DLA Troop Support Medical Supply Chain - DMMonline

[Prime Vendor Program](#)

[Pharmaceuticals](#)

[Medical/Surgical](#)

[Equipment](#)

[Readiness](#)

[ECAT](#)

[Site Login](#)

[Achilles Hamilothoris](#)

[Logout](#)

Nat'l Contracts Compliance

- [Compliance Report](#)
- [Contract List](#)
- [Compliance Summary Report](#)
- [Help](#)

- [CDMIA Home](#)

National Contracts Compliance Report

The National Contracts tool that can be used by DLA Troop Support Medical Supply Chain and their customers to monitor those Medical Treatment Facilities (MTFs) who are purchasing equivalent Non-Contract Items, instead of the mandatory use Contracted Items. It will list those MTFs who are purchasing Non-Contracted Items during that specific quarter. Furthermore, it shows the Potential Lost Savings if the MTFs had purchased the Equivalent Contract Item.

Helpful Links

- [Customer Assistance](#)
- [Site Map](#)
- [Visiting Our Organization](#)
- [DLA Troop Support Website](#)
- [Government Medical Websites](#)



Mandatory Use National Contracts

- ▶ National contracts are joint agreements with VA to leverage buying power & maximize savings
- ▶ All joint national contracts are mandatory use contracts
 - If you have the drug on your formulary or non-formulary shelf, you must buy national contracted NDC
 - Buying other available NDCs from the same manufacturer or repackaged NDCs will count against compliance numbers (Report strictly looks at NDCs)
- ▶ Document why items cannot be purchased—P&T Committee Meeting minutes?
 - Manufacturer Backorder / Product Unavailable / etc.
 - Clinical decisions / med necessary / etc.

National Contract List Spreadsheet Example

	A	B	C	D	E	F	G	H	I	J	K
1	National Contracts Drug List										
2	Contract Number	NDC	Package Price	Drug Name	Package Size	Price per Unit	Dosage Form	Drug Strength	Unit of Measure	Effective Date	Expiration Date
3	VA797P0206	00378025501	\$4.04	ALBUTEROL SULFATE	100	\$0.04	TABLET	2 MG	EA	7/1/2010	6/30/2011
4	VA797P0206	00378057201	\$5.67	ALBUTEROL SULFATE	100	\$0.06	TABLET	4 MG	EA	7/1/2010	6/30/2011
5	VA797P0097	66685100100	\$3.05	AMOX TR/POTASSIUM CLAVULANATE	20	\$0.15	TABLET	875-125 MG	EA	1/19/2009	11/18/2011
6	VA797P0097	66685100200	\$6.27	AMOX TR/POTASSIUM CLAVULANATE	20	\$0.31	TABLET	500-125 MG	EA	1/19/2009	11/18/2011
7	VA797P0097	66685101100	\$1.85	AMOX TR/POTASSIUM CLAVULANATE	50	\$0.04	SUSPENSION	200-28.5/5	ML	11/19/2008	11/18/2011
8	VA797P0097	66685101200	\$0.92	AMOX TR/POTASSIUM CLAVULANATE	50	\$0.02	SUSPENSION	400-57MG/5	ML	1/19/2009	11/18/2011
9	VA797P0097	66685101101	\$3.14	AMOX TR/POTASSIUM CLAVULANATE	75	\$0.04	SUSPENSION	200-28.5/5	ML	4/1/2008	11/18/2011
10	VA797P0097	66685101201	\$1.95	AMOX TR/POTASSIUM CLAVULANATE	75	\$0.03	SUSPENSION	400-57MG/5	ML	1/19/2009	11/18/2011
11	VA797P0097	66685101102	\$5.14	AMOX TR/POTASSIUM CLAVULANATE	100	\$0.05	SUSPENSION	200-28.5/5	ML	4/1/2008	11/18/2011
12	VA797P0097	66685101202	\$0.86	AMOX TR/POTASSIUM CLAVULANATE	100	\$0.01	SUSPENSION	400-57MG/5	ML	1/19/2009	11/18/2011
13	VA797P0039	00781194133	\$17.72	AZITHROMYCIN	3	\$5.91	TABLET	500 MG	EA	4/1/2008	10/22/2011
14	VA797P0039	00781149668	\$10.35	AZITHROMYCIN	6	\$1.73	TABLET	250 MG	EA	6/24/2008	10/22/2011
15	VA797P0039	00781149631	\$5.72	AZITHROMYCIN	30	\$0.19	TABLET	250 MG	EA	6/24/2008	10/22/2011
16	VA797P0039	00781149731	\$25.37	AZITHROMYCIN	30	\$0.85	TABLET	600 MG	EA	6/24/2008	10/22/2011
17	VA797P0039	00781194131	\$56.85	AZITHROMYCIN	30	\$1.90	TABLET	500 MG	EA	6/24/2008	10/22/2011
18	VA797P0039	00781149669	\$48.24	AZITHROMYCIN	50	\$0.96	TABLET	250 MG	EA	4/1/2008	10/22/2011
19	VA797P0086	00832108000	\$3.20	BENZTROPINE MESYLATE	100	\$0.03	TABLET	0.5 MG	EA	8/2/2010	8/1/2011
20	VA797P0086	00832108100	\$2.15	BENZTROPINE MESYLATE	100	\$0.02	TABLET	1 MG	EA	8/2/2008	8/1/2011
21	VA797P0086	00832108200	\$2.36	BENZTROPINE MESYLATE	100	\$0.02	TABLET	2 MG	EA	8/2/2008	8/1/2011
22	VA797P0086	00832108110	\$17.85	BENZTROPINE MESYLATE	1000	\$0.02	TABLET	1 MG	EA	8/2/2008	8/1/2011
23	VA797P0086	00832108210	\$18.80	BENZTROPINE MESYLATE	1000	\$0.02	TABLET	2 MG	EA	8/2/2008	8/1/2011
24	VA797P0207	00185012801	\$6.80	BUMETANIDE	100	\$0.07	TABLET	0.5 MG	EA	8/4/2010	8/3/2011
25	VA797P0207	00185012905	\$32.00	BUMETANIDE	500	\$0.06	TABLET	1 MG	EA	8/4/2010	8/3/2011
26	VA797P0207	00185013005	\$36.50	BUMETANIDE	500	\$0.07	TABLET	2 MG	EA	8/4/2010	8/3/2011
27	VA797P0035	60429094601	\$9.22	BUPROPION HCL	100	\$0.09	TABLET	75 MG	EA	10/29/2010	10/28/2011

NCCR Results Example—Tab 1

6 Report Type: All Nationally Contracted Drugs and the facility's compliance

7 Legend: drugs purchased off contract within specified period

8 drugs purchased on contract within specified period

9 drugs not purchased during specified period

10

11	NDC	Drug Name	Drug Strength	Package Size	On Contract Quantity	On Contract Sales	Off Contract Quantity	Off Contract Sales	Total Quantity	Total Sales	Loaded Unit Price	Contract Cost	Excess Cost	Compliance by Quantity
66	00378009401	CARBIDOPA/LEVODOPA : TABLET, SUSTAINED ACTION	50MG-200MG	100	6	\$134.70	0	\$0.00	6	\$134.70	\$22.45	\$134.70	(\$0.00)	100.00%
67	00378021301	CHLORTHALIDONE : TABLET	50MG	100	6	\$59.70	0	\$0.00	6	\$59.70	\$9.95	\$59.67	\$0.03	100.00%
68	00378022201	CHLORTHALIDONE : TABLET	25MG	100	19	\$137.75	0	\$0.00	19	\$137.75	\$7.25	\$137.75	\$0.00	100.00%
69	60429090230	CLOBETASOL PROPIONATE : CREAM (GRAM)	0.05%	30	0	\$0.00	0	\$0.00	0	\$0.00	\$0.00	\$0.00	\$0.00	0.00%
70	00168016315	CLOBETASOL PROPIONATE : CREAM (GRAM)	0.05%	15	0	\$0.00	24	\$30.00	24	\$30.00	\$1.11	\$26.63	\$3.37	0.00%
71	51672125801	CLOBETASOL PROPIONATE : CREAM (GRAM)	0.05%	15	0	\$0.00	18	\$122.94	18	\$122.94	\$1.11	\$19.97	\$102.97	0.00%
72	51672125803	CLOBETASOL PROPIONATE : CREAM (GRAM)	0.05%	60	0	\$0.00	24	\$542.88	24	\$542.88	\$2.48	\$59.56	\$483.32	0.00%
73	60429090245	CLOBETASOL PROPIONATE : CREAM (GRAM)	0.05%	45	0	\$0.00	0	\$0.00	0	\$0.00	\$0.00	\$0.00	\$0.00	0.00%
74	60429090260	CLOBETASOL PROPIONATE : CREAM (GRAM)	0.05%	60	0	\$0.00	0	\$0.00	0	\$0.00	\$0.00	\$0.00	\$0.00	0.00%
75	60429090215	CLOBETASOL PROPIONATE : CREAM (GRAM)	0.05%	15	6	\$6.66	0	\$0.00	6	\$6.66	\$1.11	\$6.66	\$0.00	100.00%
76	60429090130	CLOBETASOL PROPIONATE : OINTMENT (GRAM)	0.05%	30	0	\$0.00	0	\$0.00	0	\$0.00	\$0.00	\$0.00	\$0.00	0.00%
77	51672125903	CLOBETASOL PROPIONATE : OINTMENT (GRAM)	0.05%	60	0	\$0.00	38	\$859.56	38	\$859.56	\$2.61	\$99.11	\$760.45	0.00%
78	60429090145	CLOBETASOL PROPIONATE : OINTMENT (GRAM)	0.05%	45	0	\$0.00	0	\$0.00	0	\$0.00	\$0.00	\$0.00	\$0.00	0.00%
79	60429090160	CLOBETASOL PROPIONATE : OINTMENT (GRAM)	0.05%	60	0	\$0.00	0	\$0.00	0	\$0.00	\$0.00	\$0.00	\$0.00	0.00%
80	51672125901	CLOBETASOL PROPIONATE : OINTMENT (GRAM)	0.05%	15	0	\$0.00	6	\$40.98	6	\$40.98	\$0.99	\$5.96	\$35.02	0.00%


NCCR Results Tab 2 Example— When Purchased/Recommended NDC

	NDC	Drug Name	Compliance	National Contract NDC	Order Date	Order Quantity	Contract Number	Call Number	Unit of Measure	Line Item Amount	Unit Price
5											
6	66685101202	AMOX TR-K CLV 400-57/5 SUSP	Yes		3/2/2011	3	SPM20005D3005	BM37	EA	\$2.52	\$0.84
7	66685101202	AMOX TR-K CLV 400-57/5 SUSP	Yes		3/3/2011	4	SPM20005D3005	BM49	EA	\$3.36	\$0.84
8	66685101202	AMOX TR-K CLV 400-57/5 SUSP	Yes		3/7/2011	5	SPM20005D3005	BM77	EA	\$4.20	\$0.84
9	00378116591	BUSPIRONE HCL 15 MG TABLET	Yes		3/15/2011	7	SPM20005D3005	BN66	EA	\$13.65	\$1.95
10	00378114005	BUSPIRONE HCL 5 MG TABLET	Yes		3/23/2011	1	SPM20005D3005	BP46	EA	\$9.84	\$9.85
11	00378022201	CHLORTHALIDONE 25 MG TABLET	Yes		3/4/2011	1	SPM20005D3005	BM69	EA	\$7.25	\$7.25
12	60429090215	CLOBETASOL 0.05% CREAM	Yes		3/1/2011	4	SPM20005D3005	BM23	EA	\$4.44	\$1.11
13	51672125801	CLOBETASOL 0.05% CREAM	No	60429090215	3/7/2011	18	SPM20005D3005	BM82	EA	\$122.94	\$1.11
14	51672125803	CLOBETASOL 0.05% CREAM	No	60429090260	3/21/2011	12	SPM20005D3005	BP26	EA	\$271.44	\$2.48
15	60429090215	CLOBETASOL 0.05% CREAM	Yes		3/28/2011	2	SPM20005D3005	BP82	EA	\$2.22	\$1.11
16	51672125901	CLOBETASOL 0.05% OINTMENT	No	60429090115	3/7/2011	6	SPM20005D3005	BM82	EA	\$40.98	\$0.99
17	51672125903	CLOBETASOL 0.05% OINTMENT	No	60429090160	3/9/2011	8	SPM20005D3005	BN13	EA	\$180.96	\$2.61
18	51672125903	CLOBETASOL 0.05% OINTMENT	No	60429090160	3/16/2011	6	SPM20005D3005	BN79	EA	\$135.72	\$2.61
19	51672125903	CLOBETASOL 0.05% OINTMENT	No	60429090160	3/30/2011	3	SPM20005D3005	BQ12	EA	\$67.86	\$2.61
20	00056016970	COUMADIN 1 MG TABLET	No	60429078401	3/2/2011	3	SPM20005D3005	BM37	EA	\$156.84	\$3.14
21	00056016970	COUMADIN 1 MG TABLET	No	60429078401	3/7/2011	1	SPM20005D3005	BM77	EA	\$52.28	\$3.14
22	00056016970	COUMADIN 1 MG TABLET	No	60429078401	3/8/2011	4	SPM20005D3005	BM96	EA	\$209.12	\$3.14
23	00056016970	COUMADIN 1 MG TABLET	No	60429078401	3/25/2011	1	SPM20005D3005	BP70	EA	\$52.28	\$3.14
24	00056016970	COUMADIN 1 MG TABLET	No	60429078401	3/30/2011	1	SPM20005D3005	BQ09	EA	\$52.28	\$3.14
25	00056017090	COUMADIN 2 MG TABLET	No	60429078510	3/2/2011	1	SPM20005D3005	BM37	EA	\$545.61	\$29.56
26	00056017090	COUMADIN 2 MG TABLET	No	60429078510	3/10/2011	2	SPM20005D3005	BN26	EA	\$1,091.22	\$29.56
27	00056017090	COUMADIN 2 MG TABLET	No	60429078510	3/17/2011	1	SPM20005D3005	BN98	EA	\$545.61	\$29.56

National Contract Items

- ▶ Announcements are sent out by DLA Troop Support Medical
- ▶ Per the prime vendor contract, the customer must initiate the request
 - Provide NDC information and estimated monthly utilization to the prime vendor
- ▶ Make sure to change your shelf tag to reflect the national contracted NDC

National Contract Tracking - DoD Pharm Compliance %



	Jan-11	Feb-11	Mar-11	Apr-11	May-11	Jun-11	Jul-11	Aug-11	Sep-11	Oct-11
USA	81.0%	82.2%	82.7%	84.6%	82.7%	82.0%	85.5%	87.2%	88.7%	88.8%
USAF	85.6%	87.0%	89.4%	90.6%	91.4%	92.5%	92.3%	93.6%	93.5%	94.4%
USN	80.9%	80.9%	83.9%	82.9%	83.5%	83.9%	85.2%	86.8%	85.7%	83.5%
USCG	79.8%	79.9%	86.5%	86.3%	85.8%	83.4%	83.5%	91.1%	80.5%	84.3%
Average	81.8%	82.5%	85.6%	86.1%	85.9%	85.4%	86.6%	89.7%	87.1%	87.7%

* Please note there are instances when contract items may be unavailable due to variables such as shortages, facilities may need to set up monthly prime vendor (PV) requirements, time needed for PV to stock, Clinical Decisions, etc.

Universal Data Repository (UDR)



DEFENSE LOGISTICS AGENCY Logistics Information Service

[Home](#) | [Products](#) | [Services](#) | [Programs](#) | [Cataloging](#) | [Log Tools](#) | [Supplier](#) | [Training](#) | [Library](#)

UDR Home
▸ DEPMEDS
Glossary
What's New
UDR Web Links
▸ UDR CD-ROM
Log Off



[Log On](#)

[Registration Form](#)

Welcome to the Universal Data Repository (UDR) Web. The UDR Medical Program, sponsored by the Defense Medical Logistics Standard Support (DMLSS) Office, is an automated information system consolidating medical and pharmaceutical information. The UDR provides a single source of current data for product and price comparison. Searches are available for pharm and med/surg items, Service Assemblage data, and Decentralized Blanket Purchase Agreements (DBPAs), and provide summary, equivalent and detail information. The UDR is a FOR OFFICIAL USE ONLY (FOUO) product. To obtain an account to the UDR Web, the user must complete the user registration form on the link provided (under Log On box). Enter all required and relevant fields and fax to the number provided. Upon receiving signed registration verification page, and e-mail notification from user, DLA Logistics Information Service (Access Control) will forward a password to the external user (registrar). For more information, contact the DLA Logistics Information Service Contact Center at 1-877-352-2255 or e-mail: dlacontactcenter@dla.mil

<https://www.dlis.dla.mil/udr/frmLogon.aspx>

Search for Additional Items, Items on Contract, AWP, NSNs, etc.

As of 5/23/08, UDR became CAC only enabled. The following steps are provided

UDR Results Example

	Contract Num	NDC	NSN	Short Description	SOS	U/P	Packaging of U/P	Manuf	Price	UM Price	SBI	Item Description	Av Whsl
D			6505-01-146-5130	IBUPROFEN TABLETS100S	SMS	BT	100TT	MERCK SHARP & DOHME CORP. DIV CORPORATE HEADQUARTERS	5.68	0.05680	N	IBUPROFEN TABLETS USP 600MG 100 TABLETS PER BOTTLE	0.00000
D			6505-01-326-4475	IBUPROFEN TABLETS500S	SMS	PG	500TT	CONNEY SAFETY PRODUCTS	42.57	0.08514	Y	IBUPROFEN TABLETS USP 200MG 500 TABLETS PER PACKAGE	0.00000
D E	V797P-5237B	00904-5186-40		IBUPROFEN 600 MG TABLET	PVP	BO	1BT of 500EA	MAJOR PHARM.	14.10	0.02820	Y	IBUPROFEN 600 MG TABLET 500	113.29000
D E	V797P-5237B	00904-5186-60		IBUPROFEN 600 MG TABLET	PVP	BO	1BT of 100EA	MAJOR PHARM.	4.01	0.04010	Y	IBUPROFEN 600 MG TABLET 100	27.39000
D E	V797P-5237B	00904-5187-40	6505-01-214-9062	IBUPROFEN 800 MG TABLET	PVP	BO	1BT of 500EA	MAJOR PHARM.	19.33	0.03866	Y	IBUPROFEN 800 MG TABLET 500	143.69000
D E		00904-5187-40	6505-01-214-9062	IBUPROFEN TABS 500S	SMS	BT	500EA	MAJOR PHARMACEUTICALS INC	18.05	0.03610	N	IBUPROFEN TABLETS USP 800 MG 500 TABLETS PER BOTTLE	0.00000
D		00904-5187-60	6505-01-214-9061	IBUPROFEN TABS 100S	SMS	BT	100TT	MAJOR PHARMACEUTICALS INC	4.78	0.04780	N	IBUPROFEN TABLETS USP 800 MG 100 TABLETS PER BOTTLE	0.00000
D E	V797P-5237B	00904-5187-60	6505-01-214-9061	IBUPROFEN 800 MG TABLET	PVP	BO	1BT of 100EA	MAJOR PHARM.	5.16	0.05160	Y	IBUPROFEN 800 MG TABLET 100	35.95000
D E	V797P-5237B	00904-5309-09		CHILDREN IBUPROFEN 100 MG/5 ML	PVP	BO	1BT of 240ML	MAJOR PHARM.	4.18	0.01741	Y	IBUPROFEN 100 MG/5ML ORAL SUSP 240	7.50000
D E	V797P-5237B	00904-5309-20		CHILDREN IBUPROFEN 100 MG/5 ML	PVP	BO	1BT of 120ML	MAJOR PHARM.	3.33	0.02775	Y	IBUPROFEN 100 MG/5ML ORAL SUSP 120	5.39000

Readiness Management Application (RMA)

Readiness Management Application - Microsoft Internet Explorer

Previous Search New Search Save Search Print Download Welcome to RMA

Search RMA

NSN Assembly Requirements Commercial Info Contracts Readiness Assessments My Searches

Search Criteria

Search by FSC: and Keyword: Go

Search by Keyword: Go

Search by NSN: Go

Paste a number of NSNs (1 through 1000 inclusive) that you copied from Excel or Access:

Use this criteria to search RMA for a particular FSC or NSN

- Could do NSN/NDC comparisons/searches
- See which items have Contingency Contracts in which supplies may be available if normal pipeline out (i.e., shortages)
 - Also:
 - Kitting / Assembly Management
 - Contingency Requirements & Contract Management
 - Commercial Sales Visibility
 - Readiness Assessment Modeling (Command Level)

Readiness Contract Items (Example)

RMA Home Logout

Logged In as - Jose Ramos

Previous Search New Search Save Search Print Download

Welcome to RMA

NSN Description and Packaging	
Description:	DOXYCYCLINE HYCLATE CAPSULES USP 100MG 500 CAPSULES PER BOTTLE
UI:	BT
QUI:	500
QUOM:	EA
Supply Chain Event:	No
JDF:	No
Associated NSNs:	Yes

Contract Coverage		
Coverage	DSCP	Other
Depot	0	N/A
DSCP CEC	<u>168</u>	No
DSCP SR	0	No
DSCP VMI	<u>48</u>	No
PVWRM-N	0	No
PVWRM-S	<u>40</u>	No
PVWRM-W	0	No
Total	256	

Services Requirements		
Service	60 Days	180 Days
USAF	0	0
ARMY	102	330
USN	227	583
USMC	68	199
Services Requirements	397	1112
DSCP Total Coverage /w Replenishment	357	1112
Readiness Shortfall	40	0
Assembly Component Requirements (for info only)	0	0

NSN Overview **6505000095063**

Product of Choice
 Assemblies
 NSN Detail
 Associated NSNs
 Sales/ Equivalents
 Requirements
 Contracts
 Readiness Assessment

JDF items will be highlighted

Federal Logistics Information System Commercial Identifiers				
Part Num/NDC	Manufacturer	Obs. Date	Replace. Item	Comm. Sales
00143314205	WEST-WARD PHARMACEUTICAL CORP			Y
00364203305	CARDINAL HEALTH 100 INC	8/30/2001	00591544005	N
00603348128	GENERIC'S BIDCO I LLC			Y
53489011905	MUTUAL PHARMACEUTICAL COMPANY INC.			Y

Recommended Products of Choice													
Part Num/NDC	Mfg.	Description	UI	QUI	UM	FLIS	Pricing Avail	Contin. Contract	ECAT Sales	PV Sales	Comm. Sales	PVON	
00143314205	WEST-WARD PHARMACEUTICAL	W-W DOXYCYCLINE CAP 100MG 500 3142-05	BT	500	EA	Y	Y	<u>Y</u>	N	Y	310187	N	

DLA Electronic Catalog (ECAT)

ECAT Order Products 2.4.5.0 Home Search Browse S. O. M. Help Email Profile Supplier Logout
Logged In As- Achilles Hamilothoris

Search Our Product Catalogs Items: 0 | Total: \$00,000.00

Check if DVD Order:

Search within supplier: Search All Suppliers

Limit search to geographic regions:
 CONUS OCONUS Alaska Hawaii Puerto Rico

Limit search to DoDAAC:

1 By Product Number

Part Number
Part Number

Enter Number

Search

2 By Product Name

Enter Keywords
hydrogen peroxide 16oz

Narrow Further By Manuf. Name

And / Or Supplier Name

Search

3 By Item ID

First, select a supplier

Second, select a catalog

Third, select an item

Search

4 By Category

First, select a Product Category

Search

Search for Additional Items Not Available via the Prime Vendor—Search Prior to DVD !

ECAT Results Example

ECAT *Order Products* 2.4.5.0

Home Search Browse S. O. M. Help Email Profile Supplier Logout

Logged In As- Achilles Hamilothoris

Search Results New Search

13 product(s) found for keyword = hydrogen peroxide 16oz
Regions Searched: All geographic regions were searched.

Select All Items	Sort By: Relevance	Enter Qty.	Add to Cart
Select Item	Hydrogen Peroxide 16oz/Bt Catalog Name Henry Schein Dental CONUS Catalog Part # 1023516 Price \$0.84 UoI Each Ld. Time 3 Min/Mult 1 / 1 Supplier ID: 900010206 Catalog ID: 446 Item ID: 2038892	<input type="text"/>	Add to Cart
Select Item	Hydrogen Peroxide 16oz/Bt Catalog Name Henry Schein Dental OCONUS Catalog Part # 1023516 Price \$1.05 UoI Each Ld. Time 10 Min/Mult 1 / 1 Supplier ID: 900010206 Catalog ID: 479 Item ID: 2069571	<input type="text"/>	Add to Cart
Select Item	HYDROGEN PEROXIDE 3% 16OZ HUMCO EA 4329868 Catalog Name Dental Health Products CONUS Catalog Part # 880-2454106 Price \$2.08 UoI Each Ld. Time 5 Min/Mult 1 / 1 Supplier ID: 900010215 Catalog ID: 391 Item ID: 2105993	<input type="text"/>	Add to Cart
Select Item	PEROXIDE HYDROGEN 16OZ. Catalog Name GSS Lab VWR AK/HI Catalog Part # VWR33502644EA Price \$2.02 UoI Each Ld. Time 15 Min/Mult 1 / 1 Supplier ID: 900010008 Catalog ID: 1004 Item ID: 2815206	<input type="text"/>	Add to Cart

Selected Items
Add To Reorder

Add **"Selected Items"** to a Reorder List

Select 3 Items to Compare Add selected items to your cart

Compare Items
Add to Cart

Cart Table

Build your cart by adding items from the results table

Totals are updated with each new item Proceed with your order

Items: 0
Total: \$0.00

FREE ISSUE LIST

- Free pharmaceutical/diagnostic products & free shipping
- Products will have no less than six-months dating
- “First Come, First Serve” basis

<https://dmmonline.dscp.dla.mil/Portal/Pharmaceutical/PharmGpmDrawdown.aspx>

	NSN Unit of Issue	NSN Qty Unit of Issue (Pcs/Unit)	Manufacturer	NDC	Contractor Unit of Sale	Contractor quantity unit of sale (Pcs/Unit)	Contractor Units of Sale Text Description	Contract Price Contractor Unit of Sale	Qty Available for Free Issue	GPM Value	Description	Qty Requested	Requestor's Document Number
1													
2	PG	25	Abraxis	63323-0915-01	PG	25	5 vials per packag	38.75	55	\$2,131.25	Heparin Sodium Inj, 20000 un/ml, 1 ml, vial, 25 per		
3	PG	10	Abraxis	63323-0383-10	PG	10	0 vials per packag	57.10	719	\$41,054.90	Neostigmine Methylsulfate Inj, 1 mg/ml, 10 ml, 10 per		
4	VI	10	Abraxis	63323-0344-10	VI	10	1-10 ml vial - MIN ORDER MULTIPLE OF 25	1.80	966	\$1,738.80	Sodium Injection, Sterile, USP, 250 mg, 10 ml, vial		
5	PG	25	Abraxis	63323-0024-25	PG	25	5 vials per packag	24.00	837	\$20,088.00	Mannitol Inj, 25%, 50 ml, sdu, 25 per		

Mr. Michael Brywka

Phone: 215-737-5775 (DSN 444)

Michaelbrywka.ctr@dla.mil

Mr. José Ramos

Phone: 215-737-2134 (DSN 444)

Jose.ramos@dla.mil

Contact Information

Maj Achilles Hamilothoris DSN 444-2188
achilles.hamilothoris@us.af.mil

LCDR Tiffany Scott DSN 444-3321
tiffany.scott@dla.mil

CDR Jay Peloquin DSN 444-2839
jay.peloquin@dla.mil

Mr. Jose Ramos DSN 444-2134
jose.ramos@dla.mil

Ms. Doris Anne Downes DSN 444-0762
dorisanne.downes@dla.mil

Comm: (215) 737-XXXX

Review of August 2011 P&T Committee Meeting

Dave Meade, PharmD, BCPS
Clinical Pharmacist

August 2011 DoD P&T Committee Meeting

- ▶ **Uniform Formulary Class Reviews**
 - Contraceptive Agents
 - Oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
 - Phosphodiesterase-5 Inhibitors (PDE-5s)
 - Decision pending

August 2011

DoD P&T Committee Meeting

- ▶ **New Drugs in Previously Reviewed Classes**
 - Aliskiren/Amlodipine/HCTZ (Amturnide) tablets
 - Azilsartan medoxomil tablets (Edarbi)
 - Bromocriptine mesylate (Cycloset) tablets
 - Buprenorphine transdermal system (Butrans)
- ▶ **Utilization Management**
 - Singulair Prior Authorization
 - Simvastatin 80 mg and Simcor BCF status
 - Rosiglitazone (Avandia) REMS

Uniform Formulary Class Reviews: Contraceptive Agents

Class Definition

- ▶ Divided into the following categories:
 - Oral contraceptives
 - Monophasic w/ 10 mcg EE
 - Monophasic w/ 20 mcg EE
 - Monophasic w/ 25 mcg EE
 - Monophasic w/ 30 mcg EE
 - Monophasic w/ 35 mcg EE
 - Monophasic w/ 50 mcg EE
 - Biphasics
 - Triphasics
 - Quadriphasics
 - Progestin-only
- ▶ Non-oral (Miscellaneous) contraceptives
- ▶ Emergency contraceptives



Oral Contraceptives

Clinical Conclusion

- ▶ Wide variety of oral contraceptive products currently on the UF. The differences among these products include estrogen content, progestogen content, regimen, phasic formulation, non-contraceptive benefits (e.g., acne), and route of administration
- ▶ No clinically relevant differences in contraceptives effectiveness among the different oral contraceptives
 - Lo Loestrin Fe and LoSeasonique have the highest pearl indices
- ▶ Most, if not all, combined contraceptives offer non-contraceptive benefits, including control of heavy menstrual bleeding or irregular cycles, and reduction of acne, dysmenorrhea, endometriosis pain, and menstrual migraines, regardless of FDA labeling

Clinical Conclusion

- ▶ Most commonly reported adverse effects of oral contraceptives include breast tenderness, headache, migraine, nausea, nervousness, vomiting, dizziness, weight gain, fluid retention, tiredness, decline of libido, and increased blood pressure
- ▶ Based on epidemiological data, the risk of VTE with drospirenone is about 2–3 times higher than levonorgestrel-containing oral contraceptives; this risk appears similar to the risk with the third-generation progestins (e.g., desogestrel)
 - FDA review of these studies is in progress, results will be available Dec 8, 2011
- ▶ Given the lack of substantial differences between products with regard to contraceptive effectiveness, the choice of a specific contraceptive product may depend on the individual patient's characteristics

Miscellaneous Contraceptives

Class Definition

Product	Approval date/ Patent expiration	Generics	Formulation	Estrogen (mcg)	Progestin (mg)	Active
Depo-Provera IM	1982/ expired	Yes	IM	-	MPA 0.15	84
Depo-SubQ Provera	2004/ 2020	No	SubQ	-	MPA 0.15	84
NuvaRing	2001/ 2018	No	Ring	EE 15	ETG 0.12	21
Ortho Evra	2001/ 2015	No	Patch	>EE 50*	NEMG 0.20	21

* Previously thought to be ~ 35 mcg EE, recent PK study shows ~60% higher estrogen exposure (>50 mcg)

Clinical Conclusion

- ▶ Contraceptive products have alternative routes of administration, including injections (DMPA), a transdermal patch (Ortho Evra), and a vaginal ring (NuvaRing)
 - Have a role in certain patient population
- ▶ Ortho Evra and NuvaRing have similar contraceptive effectiveness as the combined oral contraceptives
- ▶ Injectable contraceptives are highly effective agents
 - No pregnancy was reported in the three, year-long trials
- ▶ Based on a comparative trial, adverse effects of the transdermal patch appear similar to a combined oral contraceptive comparator, with the exception of a higher incidence of site reactions, breast symptoms (e.g., breast tenderness), and dysmenorrhea
 - Up to two-fold increased risk of VTE

Clinical Conclusion

- ▶ Most common adverse effects of the vaginal ring were vaginitis, headache, vaginal secretion, weight gain, and nausea
- ▶ Main issues with the vaginal ring are that patients might not be comfortable with the method and the concern of deployment limitations related to storage requirements
- ▶ Women receiving injectable DMPA may lose significant BMD, may not be completely reversible
- ▶ Injectable DMPA is associated with progressive (and substantial) weight gain

Emergency Contraceptives

Class Definition

Drug Name	Next Choice	Plan B One-Step	Ella
Company	Watson (Plan B generic)	Teva	Watson
Progestin per dose (mg)	LNG 0.75	LNG 1.5	UPA 30
Approval date/ Patent expiration	2009	2009/ 2012	2010/2015
First Dose	1 pill within 72 hours after UPI	1 pill within 72 hours after UPI	1 pill within 120 hours after UPI
Second Dose	1 pill 12 hours later	None	None
RX Status	<17yo RX ≥17yo OTC	<17yo RX ≥17yo OTC	RX
Duration	72 hr	72 hr	120 hr

UPA: Ulipristal acetate

Adapted from FDA Medical Review—Ulipristal acetate (Ella). 2010.

Clinical Conclusion

- ▶ Based on the two pivotal trials, UPA is effective at preventing pregnancy following UPI
- ▶ The pregnancy rate of UPA, administered within 120 hours of unprotected intercourse, was lower than the expected pregnancy rate and also lower than the clinical relevance threshold of 4%
- ▶ The efficacy of UPA did not decrease over the 120 hours of UPI
- ▶ In 2 head-to-head comparisons with LNG, UPA was shown to be non-inferior to LNG and 1 study demonstrated that UPA prevented more unintended pregnancies when administered within 72 and 120 hours after unprotected intercourse
- ▶ UPA was shown to be well-tolerated in the clinical trials and its side effect profile is similar to that of LNG
- ▶ The most common adverse effects were headache, abdominal pain, nausea, and dysmenorrhea
- ▶ Ella is only available with a prescription
- ▶ Long-term safety remains unknown

Contraceptive Agents– Final Decision

DoD PEC Drug Class	On BCF MTFs <u>must</u> have on formulary	Not on BCF MTFs <u>may</u> have on formulary	MTFs <u>must not</u> have on formulary
Oral Contraceptives Subclass	<ul style="list-style-type: none"> • EE 20 mcg; 3 mg drospirenone (Yaz) • EE 20 mcg; 0.1 mg levonorgestrel (Lutera, Sronyx or equiv) • EE 30 mcg; 3 mg drospirenone (Yasmin) • EE 30 mcg; 0.15 mg levonorgestrel (Levora, Nordette or equiv) • EE 30 mcg; 0.15 mg levonorgestrel extended cycle (Jolessa only) • EE 35 mcg; 1.0 mg norethindrone (Norinyl 1+35, Ortho Novum 1/35 or equiv) • EE 35 mcg; 0.25 mg norgestimate (Mononessa, Ortho Cyclen or equiv) • EE 25 mcg; 0.18/0.215/0.25 mg norgestimate (Ortho Tri-Cyclen Lo) • EE 35 mcg; 0.18/0.215/0.25 mg norgestimate (Trinessa, Ortho Tri-Cyclen or equiv) • 0.35 mg norethindrone (Nor-QD, Micronor or equiv) 	<ul style="list-style-type: none"> • EE 20 mcg; 1.0 mg norethindrone • EE 20 mcg; 1.0 mg norethindrone; ferrous fumarate • EE 30 mcg; 0.3 mg norgestrel • EE 30 mcg; 0.15 mg desogestrel • EE 30 mcg; 1.5 mg norethindrone • EE 30 mcg; 1.5 mg norethindrone; ferrous fumarate • EE 35 mcg; 0.5 mg norethindrone • EE 35 mcg; 1.0 mg ethynodiol diacetate • Mestranol 50 mcg; 1 mg norethindrone • EE 50 mcg; 1 mg ethynodiol diacetate • EE 50 mcg; 0.5 mg norgestrel • EE 35 mcg; 0.5/1.0 mg norethindrone • EE 20/10 mcg; 0.15 mg desogestrel • EE 30/40/30 mcg; 0.05/0.075/0.125 mg levonorgestrel • EE 35 mcg; 0.5/1/0.5 mg norethindrone • EE 35 mcg; 0.5/0.75/1 mg norethindrone • EE 25 mcg; 0.1/0.125/0.15 mg desogestrel 	<ul style="list-style-type: none"> • EE 10 mcg; 1.0 mg norethindrone; ferrous fumarate (Lo Loestrin Fe) • EE 20 mcg/norethindrone acetate 1 mg – 24-day regimen (Loestrin 24 Fe) • EE 20 mcg; 3 mg drospirenone; levomefolate calcium 0.451mg (Beyaz) • EE 20 mcg/levonorgestrel 0.9 mg – 28-day continuous regimen (Lybrel or equiv) • EE 20/10 mcg; 0.10 mg levonorgestrel (LoSeasonique or equiv) • EE 30 mcg; 3 mg drospirenone; levomefolate calcium 0.451mg (Safyral) • EE 30 mcg; levonorgestrel 0.15 mg generics (Seasonale or equiv – excludes Jolessa) • EE 35 mcg; 0.4 mg norethindrone (Femcon Fe chew tab, Ovcon 35 or equiv) • EE 50 mcg; 1 mg norethindrone (Ovcon 50) • EE 30/10 mcg; 0.15 mg levonorgestrel (Seasonique or equiv) • EE 20/30/35 mcg; norethindrone 1 mg (Estrostep Fe or equiv) • Estradiol valerate 3/2/2/1 mg; dienogest 2/3 mg (Natazia)

Contraceptive Agents—Final Decision

DoD PEC Drug Class	On BCF MTFs <u>must</u> have on formulary	Not on BCF MTFs <u>may</u> have on formulary	MTFs <u>must not</u> have on formulary
Miscellaneous Contraceptives Subclass	None	<ul style="list-style-type: none"> ▪ Norelgestromin 0.2 mg transdermal (Ortho-Evra) ▪ Etonorgestrel 0.12 mg vaginal ring (NuvaRing) ▪ 104 mg/0.65mL depot medroxyprogesterone acetate injection (Depo-subq Provera 104) ▪ 150 mg/mL depot medroxyprogesterone acetate injection 	None
Emergency Contraceptives Subclass	<ul style="list-style-type: none"> ▪ 0.75 mg levonorgestrel (Next Choice; generic Plan B) 	<ul style="list-style-type: none"> ▪ 1.5 mg levonorgestrel (Plan B One Step) ▪ 30 mg Ulipristal acetate (Ella) 	None

Uniform Formulary Class Reviews: Oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Class Definition

Generic Name	Brand	FDA Approval Date	Patent Expiration
Celecoxib	Celebrex	12/31/1998	5/30/2014 –12/2/2015
Diclofenac/misoprostal	Arthrotec	12/24/1997	2/11/2014
Naproxen/esomeprazole	Vimovo	4/30/2010	11/27/2014–2/28/2023
Diclofenac potassium	Zipsor	4/30/2011	2019–2029
Diclofenac potassium	Cambia	generic	N/A
Diclofenac potassium	Cataflam	generic	N/A
Diclofenac sodium	Voltaren	generic	N/A
Diflunisal	Generic only	generic	N/A
Etodolac	Generic only	generic	N/A
Fenoprofen	Nalfon	generic	N/A
Flurbiprofen	Ansaid	generic	N/A
Ibuprofen	Motrin	generic	N/A
Indomethacin	Indocin	generic	N/A
Ketoprofen	Oruvail	generic	N/A
Ketorolac tromethamine	Toradol	generic	N/A
Meclofenamate	Generic only	generic	N/A
Mefenamic acid	Ponstel	generic	N/A
Meloxicam	Mobic	generic	N/A
Nabumetone	Relafen	generic	N/A
Naproxen	Naprosyn	generic	N/A
Naproxen sodium	Naprelan er	generic	N/A
Naproxen sodium	Anaprox	generic	N/A
Oxaprozin	Daypro	generic	N/A
Piroxicam	Feldene	generic	N/A
Sulindac	Clinoril	generic	N/A
Tolmetin	Tolectin	generic	N/A

Clinical Conclusion

- ▶ For short-term pain relief (<6 months), all the oral NSAIDs have a similar effect on reducing pain in adults with chronic pain from either osteoarthritis, rheumatoid arthritis, soft-tissue pain, back pain, or ankylosing spondylitis
- ▶ Zipsor was superior to placebo for reducing pain for patients after bunionectomy
- ▶ Vimovo was superior to placebo and non-inferior to celecoxib for reducing pain in patients with knee osteoarthritis
- ▶ Celecoxib had short-term GI safety benefit in meta-analyses and SUCCESS trial, but did not show benefit for long-term GI safety (CLASS trial)
- ▶ In one head-to-head trial, celecoxib plus aspirin vs naproxen plus lansoprazole plus aspirin showed no significant difference for endoscopic ulcers at 12 weeks (short-term) (Goldstein 2007 Clin Gastro&Hepat)
- ▶ Celecoxib vs diclofenac plus omeprazole showed no significant differences in terms of short-term GI safety

Clinical Conclusion

- ▶ One recent study (CONDOR) showed short-term GI safety benefit for celecoxib for the composite endpoint of upper and lower GI bleeds as compared to diclofenac plus omeprazole, primarily due to a decrease in hemoglobin due to presumed occult bleeding of GI origin (small bowel) (Chan 2020 Lancet)
- ▶ One recent good quality trial suggests that Celecoxib plus a PPI significantly lowered recurrent GI bleeding in very high-risk GI patients long-term (12-month trial) (Chan 2007 Lancet)
- ▶ Partially selective NSAIDs: Nabumetone showed short-term GI safety benefit compared to nonselective NSAIDs in a single meta-analysis of fair quality. Etodolac and Meloxicam showed no consistent differences as compared to nonselective NSAIDs
- ▶ Nonselective NSAIDs showed no differences in short-term or long-term GI safety, compared to one another
- ▶ Vimovo showed benefit in short-term GI safety as compared to EC Naproxen alone
- ▶ Vimovo showed short-term GI safety benefit in patients taking low-dose aspirin vs EC Naproxen alone
- ▶ Zipsor had insufficient duration of therapy to assess GI risk

NSAIDs– Final Decision

BCF/ECF Medications MTFs must have BCF meds on formulary	UF Medications MTFs may have on formulary	Nonformulary Medications MTFs may not have on formulary
<p>Ibuprofen 400 mg, 600 mg & 800 mg tabs (generic) Indomethacin 25 mg & 50 mg (generic) Meloxicam 7.5 mg & 15 mg (generic) Naproxen 250 mg & 500 mg; 125mg/5ml po susp (generic)</p>	<p>Celecoxib (Celebrex) Diclofenac/misoprostol (Arthrotec) Diclofenac potassium tablets (Cataflam generic) Diclofenac sodium tablets (Voltaren generic) Diflunisal Etodolac Fenoprofen Flurbiprofen Ketoprofen Ketorolac Meclofenamate Nabumetone Naproxen sodium 275 mg & 550 mg (Anaprox, generic) Oxaprozin Piroxicam Sulindac Tolmetin Naproxen/Esomeprazole (Vimovo)</p>	<p>Diclofenac potassium liquid -filled capsules (Zipsor) 25 mg Diclofenac potassium powder packets 50 mg (Cambia) Naproxen sodium ER (naprelan CR, generic) 375 mg, 500 mg, & 750 mg ER tabs, dosing card Mefenamic acid (Ponstel, generic) 250 mg</p>

New Drugs in Previously Reviewed Classes

Aliskiren / Amlodipine / Hydrochlorothiazide (Amturnide) tablets

Class Definition

Fixed Dose Combos / Direct Renin Inhibitors

Generic Name (abbreviation)	Brand (company)	FDA Approval Date	Patent Exp.
Direct Renin Inhibitors (DRI)			
Aliskiren +/- HCTZ	Tekturna; Tekturna HCT (Novartis)	May 2007 Jan 2008	2018/2015
Dual Fixed Dose Combos: ARB+CCB			
Telmisartan/amlodipine	Twynsta (BI)	Oct 2009	2014
Olmesartan/amlodipine	Azor (Sankyo)	Oct 2007	2016
Valsartan/amlodipine	Exforge (Novartis)	Jul 2007	2012–2019
Dual Fixed Dose Combos: DRI + ARB			
Aliskiren/valsartan	Valturna (Novartis)	Sep 2009	2012–2018
Triple Fixed Dose Combos: ARB+CCB+HCTZ			
Valsartan/amlodipine/HCTZ	Exforge HCT	Apr 2009	2012–2017
Olmesartan/amlodipine/HCTZ	Tribenzor	Jul 2010	2016

Background

- ▶ Type of drug
 - Fixed dose combination antihypertensive, containing
 - Aliskiren, a direct renin inhibitor (DRI)
 - Amlodipine, a dihydropyridine calcium channel blocker (DHP CCB)
 - HCTZ, a thiazide-type diuretic
- ▶ UF drug class
 - Renin–Angiotension Antihypertensive class (RAAs) due to presence of aliskiren, reviewed Aug 2010
- ▶ FDA–approved indications
 - Hypertension:
 - As add–on/switch from two of the components
 - As a substitute for the titrated components

Clinical Conclusion

- ▶ Amturnide offers no clinical advantage in terms of efficacy or safety over current RAAs formulary alternatives.
- ▶ No positive clinical outcomes have been reported with the aliskiren component.

Azilsartan medoxomil tablets (Edarbi; Takeda)

Class Definition

Marketed ARBs

Generic Name (abbreviation)	Brand (company)	FDA Approval Date	Patent Exp.
Losartan (LOS)	Cozaar (Merck)	1995	2010
Valsartan (VAL)	Diovan (Novartis)	1996	2012
Irbesartan (IRB)	Avapro (BMS/Sanofi)	1997	2012
Candesartan (CAN)	Atacand (AstraZeneca)	1998	2012
Telmisartan (TEL)	Micardis (Boehringer)	1998	2014
Eprosartan (EPR)	Teveten (Biovail)	1999	2016
Olmesartan (OLM)	Benicar (Sankyo/Forest)	2002	2016

- All are available in combo with HCTZ
- All are approved for hypertension

Background

- ▶ Type of drug
 - Azilsartan, an Angiotensin Receptor Blocker (ARB)
- ▶ UF drug class
 - Renin–Angiotensin Antihypertensive class (RAAs), reviewed Aug 2010
- ▶ FDA–approved indications
 - Hypertension: alone or in combination with other therapies
 - Indicated for initial therapy

Clinical conclusion

- ▶ For systolic blood pressure reduction, azilsartan is superior to valsartan (3–5 mmHg) and likely superior to olmesartan (1–2 mmHg)
- ▶ Based on efficacy for systolic blood pressure reduction, azilsartan should be maintained on the UF
- ▶ For safety, azilsartan offers no compelling clinical advantages or disadvantages over current RAAs formulary alternatives
- ▶ The role of azilsartan for hypertension may expand when the two–component FDC, azilsartan/ chlorthalidone, is commercially available

Bromocriptine Mesylate (Cycloset) tablets

Class Definition

Non-Insulin Diabetes Drugs		
Subclass	Generic Drug Name (Brand)	Generic Available
DPP-4	Sitagliptin (Januvia) BCF	No
	Sitagliptin+met (Janumet) BCF	No
	Saxagliptin (Onglyza)	No
	Saxagliptin +met (Kombiglyze XR)	No
GLP-1	Exenatide (Byetta)	No
	Liraglutide (Victoza)	No
TZDs	Pioglitazone (Actos)	No
	Pioglitazone+met (Actoplus Met)	No
	Pioglitazone+met ER (Actoplus Met XR)	No
	Pioglitazone/glimepiride (Duetact)	No
	Rosiglitazone (Avandia)	No
	Rosiglitazone/metformin (Avandamet)	No
	Rosiglitazone/glimepiride (Avandaryl)	No
Biguanides	Metformin IR 500, 850, 1000 mg Riomet liq 500/5; Metformin ER 500, 750 mg	Yes
	Metformin ER (Fortamet ER) 500, 1000 mg Metformin ER (Glumetza) 500, 1000 mg	No

Class Definition

Non-Insulin Diabetes Drugs		
Sulfonylureas	Chlorpropamide	Yes
	Tolazamide	Yes
	Tolbutamide	Yes
	Glimepiride	Yes
	Glipizide	Yes
	Glipizide ER	Yes
	Glyburide	Yes
	Glyburide micronized	Yes
	Glipizide/met	Yes
	Glyburide/met	Yes
AGI	Acarbose (Precose)	Yes
	Miglitol (Glyset)	No
Amylin Agonists	Pramlintide (Symlin)	No
Meglitinides	Nateglinide	Yes
	Repaglinide +/- met (Prandin, Prandimet)	No
Notes: 1. Patient must have a documented trial or contraindication for metformin or a sulfonylurea prior to receiving a drug in this subclass. 2. Patient must have a documented trial or contraindication for Byetta prior to receiving Victoza		

Background

- ▶ Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM)
- ▶ Dosage and Administration
 - Cycloset should be taken within 2 hours after waking with food
 - Initial starting dose: 0.8mg daily
 - May be ↑ by 0.8mg in weekly increments until the maximally tolerated dose is reached
 - Target dose and max dose: 4.8mg

Clinical Conclusion

- ▶ Up-titration of BRO-QR dose is required to achieve the maximum therapeutic benefit
- ▶ When used as monotherapy, BRO-QR decreased A1c 0.1% from baseline
- ▶ BRO-QR ↓ A1c 0.1–0.4% from baseline when added to a SU and a maximum of a 0.5% ↓ from baseline when combined with both MET and a SU
- ▶ There are no head-to-head studies to date and no long-term outcomes studies in progress
- ▶ BRO-QR is weight-neutral; however, more weight gain is likely when administered with a SU or TZD
- ▶ BRO-QR may have a beneficial effect on lipids and blood pressure

Clinical Conclusion

- ▶ Nausea is the primary side effect although BRO-QR is generally well-tolerated
- ▶ Similar % of serious adverse events between BRO-QR and placebo
- ▶ No increase in MACE events in the 52-week safety study
- ▶ Many potential drug interactions exist, including strong CYP 3A4 inhibitors
- ▶ Contraindicated in patients taking ergot derivatives, those with syncopal migraines, and lactating women
- ▶ According to current guidelines, place in therapy remains unknown

Buprenorphine Transdermal System (Butrans)

Butrans

Background

- ▶ Type of drug
 - Centrally acting mixed agonist–antagonist, buprenorphine, in transdermal formulation
- ▶ UF drug class
 - Narcotic analgesics—UF review in Feb 2007
 - Low–potency (Schedule III) single analgesic agent
- ▶ FDA–approved indications
 - Management of mod–to–severe chronic pain in patients requiring continuous, around–the–clock analgesia for an extended period of time
- ▶ Dosage and Administration
 - Available in 5 mcg/hr, 10 mcg/hr, and 20 mcg/hr patches
 - Dosed every 7 days
 - Maximum dose: one 20 mcg/hr patch

Clinical Conclusion

- ▶ Butrans has demonstrated efficacy in the treatment of patients with chronic low back pain but there are no head-to-head studies
- ▶ Not a viable option for patients requiring high-dose opioid therapy (>80 mg/day of morphine or equivalent)
- ▶ QT prolongation will limit its utility in some patients
- ▶ Respiratory depression can occur and reversal is not guaranteed with naloxone, a full antagonist
- ▶ Insufficient data published to clearly assess the efficacy and safety profile of Butrans
- ▶ Besides the convenience of less frequent dosing, Butrans offers no compelling clinical advantages over the narcotic analgesics on UF

New Drugs in a Previously Reviewed Class

Final Decisions

Drug	BCF	UF	NF	Comments- PA issues
Renin-Angiotensin Antihypertensive class	None	Azilsartan (Edarbi) Aliskerin/amlodipine/HCTZ (Amturnide)		Step therapy (automated PA) with the following as the step-preferred drugs: losartan ±HCTZ telmisartan ±HCTZ telmisartan/ amlodipine valsartan ±HCTZ valsartan/ amlodipine valsartan/ amlodipine/HCTZ Note: Azilsartan (Edarbi) and Aliskiren/amlodipine/HCTZ (Amturnide) are UF but behind the step
Non-Insulin Diabetes Drugs Dopamine agonists		None	Bromocriptine Mesylate (Cycloset)	Step Therapy (automated PA) with metformin and sulfonylureas as step-preferred drugs
Narcotic Analgesics Low-potency single analgesic agents		Buprenorphine transdermal system (Butrans)		Manual PA for buprenorphine transdermal system (Butrans) to ensure safe and appropriate use

Utilization Management

Montelukast (Singulair) PA History

- ▶ Leukotriene modifiers reviewed in Aug 07
 - Singulair clear market leader
 - Least cost-effective treatment for allergic rhinitis
- ▶ Price increase
 - Raises price 21¢ per tab across all POS {Now 53¢/tab}
 - Effective late July 2011
- ▶ Impact
 - ~76M tabs dispensed May 10–Apr 11
 - Est. cost = \$15.9M {→\$40.2M now}
- ▶ Limits to impact
 - Est. date of generic availability: Aug 2012
 - Multiple generics available
 - Unsure if exclusivity has been granted

Montelukast

Prior Authorization Criteria

▶ Automated PA

- All beneficiaries are passed through prior to the 19th birthday
- Automated review is performed based on **inhaled corticosteroid drugs** dispensed during the previous 180 days at a Military Treatment Facility (MTF), a retail network pharmacy, or the mail order pharmacy
- Stops claim for **Montelukast** if new patient and not on an inhaled corticosteroids (ICS)

▶ Prior Authorization Criteria

- Coverage is approved if the patient has evidence of use of a nasal corticosteroid or documents inability to tolerate steroids due to adverse effects, or has contraindications to either inhaled or intranasal corticosteroids

Simvastatin 80 mg/Vytorin 10/80 mg (Simcor)

- ▶ FDA Label change June 2011
 - Reserve simvastatin 80 mg only in patients on therapy > 12 months without signs of myopathy
 - Do not use simvastatin 80 mg in new patients
 - Do not increase simvastatin dose to 80 mg in pts taking lower doses who require additional cholesterol lowering
 - New contraindications and dose limitations added
 - Contraindications: posaconazole
 - Now contraindicated (previously ok in low dose): gemfibrozil, cyclosporine, danazol
 - Simvastatin 10 mg dose limit: verapamil, diltiazem
 - Simvastatin 20 mg dose limit: amiodarone, amlodipine, ranolazine
- ▶ P&T Committee's final decision
 - Delete simvastatin 80 mg from the BCF;
all other simvastatin strengths remain BCF (10, 20, 40 mg)

Rosiglitazone REMS Program

- ▶ Rosiglitazone products were withdrawn from supply chains on 10/18/2011
- ▶ After 11/18/2011, rxs may only be filled at specialty mail order pharmacies
- ▶ Program limits access to
 - Patients already taking rosiglitazone, who have been advised by provider of the risks and benefits
 - Patients not already taking rosiglitazone who are:
 - Unable to achieve glycemic control on other diabetes medications
 - Have been advised of the risks and benefits
 - Cannot take pioglitazone (Actos) for medical reasons
- ▶ Both patients and prescribers must enlist in the program

TRICARE Beneficiaries

- ▶ Avandia will only be available for DoD beneficiaries via 3 mail order specialty pharmacies after 11/18/2011
 - Acredo
 - McKesson
 - **Walgreens**
 - Liberty Mutual

Review of November 2011 P&T Committee Meeting


Dave Meade, PharmD, BCPS
Clinical Pharmacist

November 2011


DoD P&T Committee Meeting

- ▶ **Uniform Formulary Class Reviews**
 - Depression and Non-Opioid Pain Syndromes
 - Short-Acting Beta Agonist (SABA)
- ▶ **New Drugs in Previously Reviewed Classes**
 - Risedronate Delayed Release (Atelvia)
- ▶ **Utilization Management**
 - Abatacept SQ (Orencia)
 - Sunitinib (Sutent)
 - Tramadol ER (Conzip)

Questions?



Webcast Evaluations

- ▶ Please assist us in improving the webcast presentations by completing an anonymous, 5-question survey
 - ▶ Link: <http://www.zoomerang.com/Survey/WEB22CTVSNWFRP>
 - ▶ Thank you!
- 

PEC Contact Info

- ▶ 210-295-1271 (DSN 421-1271)
 - For PEC Clinical Staff
- ▶ 1-866-ASK 4 PEC (275-4732)
 - Pharmacy Operation Center
 - PECWEB@amedd.army.mil
 - Website issues
 - pdts.ameddcs@amedd.army.mil
 - Questions, assistance with PDTS, Business Objects
 - PECUF@amedd.army.mil
 - Clinical, formulary questions